Create Biomarker Confidence with Tissue Context

Flagship’s cTA™ Platform and Decision Support Process accelerates your biomarker-driven drug development strategies.
Upcoming Conference: Connect with us at AACR Annual Meeting, April 1-5

Flagship Biosciences Accelerates Your Path to Clinical Success

Discovery & PhI Trials

Research

Make informed early pipeline decisions that will accelerate the right clinical path.

Early Trials

Enable critical go/no-go decisions based on confirmation of action.

PhII - PhIII Trials

Efficacy Trials

Solve critical problems in experimental medicine that pose barriers to success.

Pivotal Trials

Differentiate your commercial strategy and increase probability of success.
Meeting the challenges of biomarkers

73% of oncology compounds rely on biomarker data during development, with the scientific challenges of biomarker identification and test development being the most challenging.

Tufts CSDD Impact Report – Volume 17, Number 3 (May/June, 2015)

Drug Development Support

Research

TARGET VALIDATION & HYPOTHESIS GENERATION

Flagship’s scientific strategy creates a confident path forward for your drug development strategies.

Early Trials

EXPLORATORY & EFFICACY ENDPOINTS

Flagship’s technology creates clear data for confident decisions to direct your drug development programs.

Efficacy Trials

PREDICTIVE STRATEGY BUILDING

Flagship’s clinical and regulatory operations support an accelerated companion diagnostic strategy.

Pivotal Trials

COMPANION DIAGNOSTICS

Directly create a diagnostic product to enable a differentiated commercial strategy using our technology.
SOLVE DIFFICULT TISSUE ANALYSIS CHALLENGES WITH OUR UNIQUE APPROACH

Work With Us

Breadth and depth in people and technology to deliver on any challenge
Work With Us